Endometrial Hyperplastic Processes in Premenopause

dc.contributor.author	Todjieva Nigina Iskandarovna
dc.date.accessioned	2026-01-02T11:32:15Z
dc.date.issued	2022-06-11
dc.description.abstract	Hormonal therapy administered for endometrial hyperplastic processes is essentially a countercurrent therapy aimed at correcting the menstrual cycle, eliminating overt estrogenic influences and preventing the formation of endometrial hyperplasia. Doctors currently have a wide range of treatments for endometrial hyperplasia in their arsenal. These include progestins, combined oral contraceptives (OCs), antigonadotropic drugs, and gonadaliberin agonists. We examined the clinical and morphological efficacy of Midiana OC for the prevention of recurrent endometrial hyperplasticity in patients with concomitant cardiovascular disease in premenopause.
dc.format	application/pdf
dc.identifier.uri	https://geniusjournals.org/index.php/emrp/article/view/1670
dc.identifier.uri	https://asianeducationindex.com/handle/123456789/77288
dc.language.iso	eng
dc.publisher	Genius Journals
dc.relation	https://geniusjournals.org/index.php/emrp/article/view/1670/1491
dc.source	Eurasian Medical Research Periodical; Vol. 9 (2022): EMRP; 43-45
dc.source	2795-7624
dc.subject	premenopause
dc.subject	endometrial hyperplasia
dc.subject	hormone therapy
dc.title	Endometrial Hyperplastic Processes in Premenopause
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	Peer-reviewed Article

item.page.files

pagination.showing.labelpagination.showing.detail

item.page.filesection.name: iskandarovna_2022_endometrial_hyperplastic_processes_in_pr.pdf
item.page.filesection.size: 434.82 KB
item.page.filesection.format: Adobe Portable Document Format